Stemline Therapeutics to Present at Upcoming Investor Conferences
September 20 2017 - 7:00AM
Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage
biopharmaceutical company developing novel therapeutics for
difficult to treat cancers, announced that Ivan Bergstein, M.D.,
Stemline’s CEO, will be presenting at two upcoming investor
conferences:
- The Cantor Fitzgerald Global Healthcare Conference on Monday,
September 25, 2017 at 8:00 AM ET, being held at the
InterContinental New York Barclay Hotel, New York City.
- The Ladenburg Thalmann 2017 Healthcare Conference on Tuesday,
September 26, 2017 at 8:30 AM ET, being held at the Sofitel New
York, New York City.
A webcast of each presentation can be viewed on the
company's website at www.stemline.com.
About Stemline Therapeutics
Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical
company developing novel therapeutics for difficult to treat
cancers. Stemline is developing three clinical stage product
candidates: SL-401, SL-801, and SL-701. SL-401 is a targeted
therapy directed to the interleukin-3 receptor (CD123), a cell
surface receptor expressed on a variety of malignancies including
blastic plasmacytoid dendritic cell neoplasm (BPDCN), a highly
aggressive, lethal malignancy of unmet medical need, with no
approved therapies. SL-401 was granted Breakthrough Therapy
Designation (BTD) for the treatment of patients with BPDCN. A
pivotal Phase 2 trial with SL-401 in BPDCN has completed
enrollment. An additional cohort is currently enrolling BPDCN
patients to ensure continued access to SL-401. Additional Phase 1/2
trials with SL-401, including as a single agent or in combination
with other agents, are ongoing in patients with other malignancies
including myeloproliferative neoplasms (MPN) (focused on chronic
myelomonocytic leukemia [CMML] and myelofibrosis [MF]), acute
myeloid leukemia (AML), and multiple myeloma. A Phase 1 trial of
SL-801, a novel oral small molecule reversible XPO1 inhibitor, is
enrolling patients with advanced solid tumors. Results presented at
the European Society of Medical Oncology (ESMO) Annual Congress in
September 2017 included dose escalation data of SL-801 through 6
dosing cohorts without dose limiting toxicity coupled with a 37.5%
rate of stable disease, including several cases of tumor shrinkage
in heavily pretreated patients. The ideal therapeutic dose of
SL-801 has not yet been determined and dose escalation/schedule
optimization continues. A Phase 2 trial of SL-701, an
immunotherapeutic, has completed dosing of patients with
second-line glioblastoma and patients are being followed for
outcomes including survival.
Forward-Looking Statements Some of
the statements included in this press release may be
forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the
safe harbor for forward-looking statements contained in the Private
Securities Litigation Reform Act of 1995. The factors that could
cause our actual results to differ materially include: the success
and timing of our clinical trials and preclinical studies for our
product candidates, including site initiation, institutional review
board approval, scientific review committee approval, patient
accrual, safety, tolerability and efficacy data observed, and input
from regulatory authorities including the risk that the FDA or
other ex-U.S. national drug authority ultimately does not approve
any of our product candidates; our plans to develop and
commercialize our product candidates; market acceptance of our
products; reimbursement available for our products; our available
cash and investments; our ability to obtain and maintain
intellectual property protection for our product candidates; our
ability to manufacture; the performance of third-party
manufacturers, clinical research organizations, clinical trial
sponsors and clinical trial investigators; and other risk factors
identified from time to time in our reports filed with the
Securities and Exchange Commission. Any forward-looking statements
set forth in this press release speak only as of the date of this
press release. We do not intend to update any of these
forward-looking statements to reflect events or circumstances that
occur after the date hereof.
ContactInvestor RelationsStemline
Therapeutics, Inc.750 Lexington AvenueEleventh FloorNew York, NY
10022Tel: 646-502-2307Email: investorrelations@stemline.com
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stemline Therapeutics (NASDAQ:STML)
Historical Stock Chart
From Apr 2023 to Apr 2024